US Patent

US9012508 — Administration of intravenous ibuprofen

Method of Use · Assigned to Cumberland Pharmaceuticals Inc · Expires 2030-09-14 · 4y remaining

Vulnerability score 68/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method of administering intravenous ibuprofen to reduce pain and morphine use in surgery patients.

USPTO Abstract

An effective dose of intravenous ibuprofen administered every 6 hours in surgery patients is a safe and effective way to reduce both pain and the need for morphine. In preferred embodiments, the administration of intravenous ibuprofen starts with the onset of anesthesia.

Drugs covered by this patent

Advil (ibuprofen) · Generic (originally Boots Group)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-981`	—	Advil
`U-981`	—	Advil

Patent Metadata

Patent number: US9012508
Jurisdiction: US
Classification: Method of Use
Expires: 2030-09-14
Drug substance claim: No
Drug product claim: No
Assignee: Cumberland Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.